Compound Radar

Absci Corporation (ABSI) Stock Analysis

United States · Healthcare / Biotechnology

Price $8.91
Market cap $1.53B
Next earnings Nov 16, 2026
Entry status Wait

Last updated Sep 8, 2026

Health Check

Last analyzed Sep 7, 2026

32
32/100 Avoid
  • Financial Health 25
  • Profitability 5
  • Business Quality 50
  • Balance Sheet 35
  • Cash Flow 60

Why this rating?

Health 32/100 — Avoid

Strongest Cash Flow 60/100
Softest Profitability 5/100
Wait

Entry timing is weak right now. Quality may be fine; the setup is not.

Company overview

Absci Corporation (ABSI) is a Biotechnology company in the Healthcare sector. Compound Radar rates Absci Corporation 32/100 (Avoid) due to solid business quality and elevated leverage.

Investment profile

  • Quality Moderate
  • Growth Soft
  • Balance Sheet Stretched

Financial highlights

Valuation

  • Forward P/E -13.2
  • EV/Revenue 843.26

Profitability

  • Revenue Growth -46.4%
  • Gross Margin 0.0%
  • Operating Margin -10741.5%
  • Net Margin 0.0%
  • ROE -57.7%

Financial strength

  • Cash $201.14M
  • Debt $3.83M
  • Net Cash $197.31M
  • Free Cash Flow $-94.03M
  • Current Ratio 10.63

Similar companies

Peers in Biotechnology, ranked by Financial Health.

Company Ticker
Price Current price

Latest quoted price for the name. Helps anchor the setup in today’s market level.

Health Entry

View all in Biotechnology →

FAQ

How Compound Radar scores and tracks Absci Corporation (ABSI).

View Methodology & FAQ →